Cancer, Rare Disease Drugs Among New China Approvals
Takeda, Bayer Gain Along with Dompe, Henlius
Executive Summary
Rare disease and cancer treatments are front and center in the latest batch of China new drug approvals, while biosimilars are expected to move into the spotlight.